Gastrodin and ginsenoside Rg1 in treating acute cerebral infarction

Abstract

The application belongs to the technical field of cosmetics, and specifically provides a Gastrodia elata polysaccharide-polypeptide compound and application thereof in cosmetics. The compound is a W1 / O / W2 multiple emulsion, which comprises an inner water phase, an oil phase and an outer water phase. The inner water phase contains a Gastrodia elata polysaccharide extract, an amphiphilic sodium alginate derivative and modified zein. The oil phase contains oil and a lipophilic emulsifier. The outer water phase contains a polypeptide composition and a polyelectrolyte. The Gastrodia elata polysaccharide extract is isolated in the inner water phase, and the polypeptide composition is distributed in the outer water phase. The polyelectrolyte interface film at the oil phase and O / W2 interface isolates the two from each other. The compound can avoid direct contact and interaction between polysaccharide phenolic components and polypeptides, improve the stability of active substances and the storage stability of the system, and synergistically exert the effects of antioxidation, promotion of collagen synthesis, inhibition of matrix metalloproteinase and repair of skin barrier, and can be used for preparing repair and / or anti-aging cosmetics.

Description

Technical Field

[0001] This application belongs to the field of cosmetic technology, and in particular relates to a gastrodia polysaccharide-peptide complex and its application in repair and anti-aging cosmetics. Background Technology

[0002] Skin aging is a complex biological process involving multiple mechanisms, including the accumulation of oxidative stress, accelerated degradation of collagen and elastin, loss of extracellular matrix structural integrity, and decline in skin barrier function. With age and the continued effects of environmental factors such as ultraviolet radiation, skin fibroblast activity decreases, type I collagen synthesis declines, and elastase activity increases, leading to aging characteristics such as wrinkles, sagging, and decreased elasticity. Therefore, developing functional cosmetic ingredients and formulations that can simultaneously target antioxidant activity, promote collagen synthesis, and inhibit elastase activity has significant application value.

[0003] Gastrodia elata is a perennial herbaceous plant of the Orchidaceae family. Its dried tuber has been used as a medicinal and edible herb in traditional Chinese medicine for over two thousand years. Gastrodia elata polysaccharide is one of the important active ingredients in Gastrodia elata. Studies have shown that it possesses various biological activities such as antioxidation, anti-aging, anti-inflammation, and immunomodulation, demonstrating broad application prospects in functional foods and cosmetics. The antioxidant capacity of Gastrodia elata polysaccharide is closely related to the content of phenolic hydroxyl groups in its molecular structure; extracts of Gastrodia elata polysaccharide with higher total phenol content exhibit stronger free radical scavenging ability. However, as a naturally derived polysaccharide active ingredient, Gastrodia elata polysaccharide faces the following technical bottlenecks in practical applications: First, polysaccharide molecules in aqueous solutions easily undergo non-covalent interactions (such as hydrogen bonds and electrostatic interactions) with protein or polypeptide active ingredients, leading to aggregation or inactivation of the active ingredients; second, the stability of Gastrodia elata polysaccharide in cosmetic formulations needs improvement, especially in complex systems containing multiple active ingredients, where its antioxidant activity may be reduced due to interactions with other components; third, Gastrodia elata polysaccharide has limited skin permeability, making it difficult to fully exert its efficacy when directly added to conventional cosmetic bases.

[0004] Peptide-based active ingredients (such as palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, acetyl hexapeptide-8, and copper tripeptide-1) have been widely used in anti-aging cosmetics. Among them, palmitoyl tripeptide-1 can stimulate collagen synthesis, palmitoyl tetrapeptide-7 has anti-inflammatory effects and promotes extracellular matrix repair, acetyl hexapeptide-8 exerts a botulinum toxin-like anti-wrinkle effect by inhibiting the release of acetylcholine at the neuromuscular junction, and copper tripeptide-1 helps promote wound healing and tissue repair. However, peptide ingredients also face problems such as poor stability and susceptibility to protease degradation.

[0005] In existing technologies, there are reports of combining Gastrodia elata extract with peptides in skincare products. However, this type of existing technology uses a simple physical mixing method to combine Gastrodia elata extract and peptide ingredients in the same system, which has two problems: First, the polysaccharides and phenolic compounds in Gastrodia elata extract may interact with peptides, leading to a decrease in the bioavailability of both; second, simple physical mixing cannot achieve spatiotemporal controllable release of different active ingredients, making it difficult to meet the dual needs of immediate repair and long-term anti-aging.

[0006] W / O / W multiple emulsions, with their unique "three-phase, two-membrane" structure, can dissolve and isolate active ingredients with different or even antagonistic properties within the same system, making them promising for applications in the cosmetics industry. After encapsulating active ingredients in a multiple emulsion, the inner phase active ingredients need to pass through two membranes to be released, thus achieving protection and sustained-release effects. However, the inherent thermodynamic instability of multiple emulsions limits their practical application. Specifically, in existing W / O / W multiple emulsions, during long-term storage, water-soluble active ingredients in the inner aqueous phase easily diffuse through the oil phase to the outer aqueous phase, leading to decreased encapsulation efficiency and premature release of active ingredients. This is particularly true for water-soluble active ingredients like Gastrodia elata polysaccharides, which contain a large number of phenolic hydroxyl groups; their diffusion in the oil phase and contact with peptide components in the outer aqueous phase are difficult to effectively prevent.

[0007] Therefore, there is an urgent need for a complex system and its preparation method that can effectively isolate Gastrodia elata polysaccharide and polypeptide active ingredients in the same system, maintain their respective activities, and achieve synergistic effects. Summary of the Invention

[0008] To address the aforementioned issues, this application provides a gastrodia polysaccharide-peptide complex and its application in repair and anti-aging cosmetics.

[0009] This application first provides a gastrodia polysaccharide-peptide complex, wherein the complex has a W1 / O / W2 type multiple emulsion structure, including an inner aqueous phase, an oil phase, and an outer aqueous phase; the inner aqueous phase contains gastrodia polysaccharide extract, amphiphilic sodium alginate derivative, and modified zein; the oil phase contains caprylic / capric triglyceride, polyglycerol ricinoleate, and glyceryl monostearate; the outer aqueous phase contains a peptide composition and a polyelectrolyte complex, wherein the polyelectrolyte complex comprises carboxymethyl chitosan and chitosan quaternary ammonium salt.

[0010] Furthermore, based on a total mass of 100 parts of the internal aqueous phase, the internal aqueous phase contains 8 to 12 parts of glycerol, 0.8 to 1.2 parts of sodium chloride, 0.15 to 0.25 parts of citric acid, 0.4 to 0.6 parts of sodium citrate, 0.2 to 0.3 parts of sodium hyaluronate, 0.4 to 0.6 parts of ascorbic acid, 1.0 to 2.0 parts of Gastrodia elata polysaccharide extract, 0.2 to 0.3 parts of amphiphilic sodium alginate derivative, 0.4 to 0.6 parts of modified zein, and the remainder is water. The pH value of the internal aqueous phase is 5.0 ± 0.1.

[0011] Furthermore, based on a total mass of 100 parts of the oil phase, the oil phase contains 65 to 85 parts of caprylic / capric triglyceride, 8 to 20 parts of polyglycerol ricinoleate, 2 to 8 parts of glyceryl monostearate, and 0.1 to 1 part of vitamin E.

[0012] Furthermore, based on a total mass of 100 parts of the external aqueous phase, the external aqueous phase contains 8 to 12 parts of glycerol, 2 to 3 parts of trehalose, 0.08 to 0.12 parts of citric acid, 0.3 to 0.5 parts of sodium citrate, 0.03 to 0.08 parts of disodium EDTA, 0.3 to 0.5 parts of carboxymethyl chitosan, 0.3 to 0.5 parts of chitosan quaternary ammonium salt, 0.2 to 0.3 parts of xanthan gum, 0.03 to 0.05 parts of polypeptide composition, 0.4 to 0.6 parts of phenoxyethanol, 0.1 to 0.2 parts of ethylhexylglycerol, and the balance being water. The pH value of the external aqueous phase is 5.5 ± 0.1.

[0013] Furthermore, the polypeptide composition comprises palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, acetyl hexapeptide-8, and copper tripeptide-1 in a mass ratio of 1:1:0.5:0.3.

[0014] Furthermore, the gastrodia polysaccharide extract is obtained by ultrasonic-assisted ethanol extraction and macroporous adsorption resin column chromatography purification of dried gastrodia tubers, and the total phenol content of the gastrodia polysaccharide extract, calculated as gallic acid, is not less than 40%.

[0015] Furthermore, the amphiphilic sodium alginate derivative is an amphiphilic sodium alginate derivative obtained by grafting sodium alginate with octylamine and cyclohexylisocyanate via a Ugi reaction. Preferably, the molar ratio of the sodium alginate structural unit, octylamine, and cyclohexylisocyanate is 1:0.3:0.3.

[0016] Furthermore, the modified zein is a modified zein nanoparticle, which is formed by the composite of lipoic acid-modified zein and the Maillard reaction product of sodium caseinate-β-glucan.

[0017] This application provides a method for preparing a gastrodia polysaccharide-peptide complex, comprising the following steps: preparing an inner aqueous phase containing gastrodia polysaccharide extract, an amphiphilic sodium alginate derivative, and modified zein; preparing an oil phase containing oil and a lipophilic emulsifier; mixing the inner aqueous phase and the oil phase and sequentially performing high-speed dispersion and high-pressure homogenization to prepare a W1 / O primary emulsion; preparing an outer aqueous phase containing a peptide composition and a polyelectrolyte; mixing the primary emulsion and the outer aqueous phase and sequentially performing high-speed dispersion and polyelectrolyte layer-by-layer assembly to prepare a W1 / O / W2 multiple emulsion.

[0018] Preferably, the mass ratio of the internal aqueous phase to the oil phase is 3:7; the high-speed dispersion is carried out at a speed of 8000 rpm for 3 minutes; the high-pressure homogenization is carried out at a pressure of 40 MPa and is carried out twice; and the particle size D[4,3] of the primary emulsion is 0.5 μm to 2.0 μm.

[0019] This application also provides the application of the above-mentioned Gastrodia elata polysaccharide-peptide complex in the preparation of repair and / or anti-aging cosmetics, wherein the repair and / or anti-aging cosmetics contain the Gastrodia elata polysaccharide-peptide complex and cosmetically acceptable excipients.

[0020] Compared with the prior art, this application has the following beneficial effects: 1. This application isolates the Gastrodia elata polysaccharide extract in the inner aqueous phase and distributes the polypeptide composition in the outer aqueous phase. The polyelectrolyte interface film at the O / W2 interface of the intermediate oil phase forms an isolation barrier, so that the two do not come into contact with each other in space. This can avoid the reaction between phenolic oxidation products and polypeptide amino groups, which is beneficial to inhibiting browning of the system and polypeptide inactivation, while reducing the oxidative attack of phenolic free radicals on peptide bonds.

[0021] 2. This application introduces modified zein nanoparticles and amphiphilic sodium alginate derivatives into the aqueous phase. These two components form a nanoscale coating structure around the Gastrodia elata polysaccharide extract. The hydrophobic segments of the amphiphilic sodium alginate derivative embed into the W1 / O interface film, enhancing its thickness and density. The lipoic acid groups in the modified zein possess redox buffering capabilities, scavenging free radicals in the aqueous phase and delaying the oxidation of phenolic components in Gastrodia elata polysaccharides, thus forming complementary antioxidant protection with ascorbic acid. Furthermore, the modified zein exhibits excellent amphiphilicity and interfacial activity. The hydrophobic regions of the sodium caseinate molecule embed into the oil phase, while the hydrophilic β-glucan segments extend into the aqueous phase, forming an interfacial layer at the W1 / O interface. This interface layer works synergistically with the PGPR / GMS / Ugi-Alg composite interface membrane to increase the membrane's thickness and elastic modulus, thereby enhancing its resistance to external disturbances (such as temperature changes and shear forces) and reducing the leakage of active ingredients from the internal aqueous phase.

[0022] 3. This application incorporates a multilayer polyelectrolyte interfacial membrane at the O / W2 interface, formed by alternating deposition of carboxymethyl chitosan layers and chitosan quaternary ammonium salt layers. This multilayer membrane possesses a high charge density and a dense network structure, enabling it to inhibit the cross-interface migration of phenolic molecules through electrostatic repulsion and steric hindrance, thereby reducing the leakage of Gastrodia elata polysaccharide into the aqueous phase containing the polypeptide. The synergistic effect of the multiple barriers formed by the oil phase, the W1 / O interface composite membrane, and the multilayer polyelectrolyte interfacial membrane can improve the isolation rate of the complex for Gastrodia elata polysaccharide and inhibit the migration of active ingredients, thus improving the storage stability of the multiple emulsion and extending its shelf life. Attached Figure Description

[0023] Figure 1 This is a schematic diagram of the structure of the gastrodia polysaccharide-peptide complex (W1 / O / W2 type multiple emulsion) of Example 1 of this application.

[0024] Figure 2 This is a response surface plot showing the interaction between the amount of Gastrodia elata polysaccharide extract and the amount of modified zein added on the polysaccharide isolation rate.

[0025] Figure 3 This is a response surface plot showing the interaction between the amount of Gastrodia elata polysaccharide extract and the amount of amphiphilic sodium alginate derivative added on the polysaccharide isolation rate.

[0026] Figure 4 This is a response surface plot showing the interaction between the amount of modified zein and the amount of amphiphilic sodium alginate derivative added in this application on the polysaccharide isolation rate.

[0027] Figure 5 This is a three-dimensional bubble diagram comparing the efficacy of the embodiments of this application with that of the comparative example over 28 days on human bodies. Detailed Implementation

[0028] The technical solutions in the embodiments of this application will be clearly and completely described below with reference to the embodiments of this application. Obviously, the described embodiments are only some embodiments of this application, and not all embodiments. Based on the embodiments of this application, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of this application.

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0030] When using “including,” “having,” and “contains” as described herein, the intention is to cover non-exclusive inclusion, unless an explicit qualifying term such as “only,” “consisting of,” etc., is used, in which case another component may be added.

[0031] The terms "preferred," "more preferably," "better," and "even better" used in this application refer to embodiments of this application that provide certain beneficial effects under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. Furthermore, the description of one or more preferred embodiments does not imply that other embodiments are unavailable, nor is it intended to exclude other embodiments from the scope of this application. That is, in this application, "preferred," "more preferably," "better," and "even better" are merely descriptions of implementations or embodiments with better effects, but do not constitute a limitation on the scope of protection of this application.

[0032] In this application, terms such as "further," "even more," and "particularly" are used for descriptive purposes and indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0033] In this application, "at least one" means one or more, such as one, two, or more. "Multiple" or "several" means at least two, such as two, three, etc., and "multi-layered" means at least two layers, such as two layers, three layers, etc., unless otherwise explicitly specified. In the description of this application, "several" means at least one, such as one, two, etc., unless otherwise explicitly specified.

[0034] When a numerical range is disclosed herein, the range is considered continuous and includes the minimum and maximum values ​​of the range, as well as every value between the minimum and maximum values. Furthermore, when the range refers to integers, it includes every integer between the minimum and maximum values ​​of the range. Additionally, when multiple ranges are provided to describe a feature or characteristic, the ranges may be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges to which they are incorporated.

[0035] Unless otherwise specified, all steps in this application may be performed sequentially or randomly. For example, the method comprising steps (a) and (b) indicates that the method may include steps (a) and (b) performed sequentially, or it may include steps (b) and (a) performed sequentially. For example, the mention that the method may also include step (c) indicates that step (c) may be added to the method in any order; for example, the method may include steps (a), (b), and (c), or it may include steps (a), (c), and (b), or it may include steps (c), (a), and (b), etc. Unless otherwise stated, singular terms may include plural forms and should not be construed as having a quantity of one.

[0036] The present application will be further illustrated by the following examples, but these examples do not limit the scope of the present application.

[0037] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in this application, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as commonly understood by one of ordinary skill in the art. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. All reagents or instruments whose manufacturers are not specified are conventional products that can be purchased commercially. In addition to the specific methods, equipment, and materials used in the embodiments, based on the knowledge of the prior art possessed by one of ordinary skill in the art and the description in this application, any prior art methods, equipment, and materials similar to or equivalent to those described, used, or made by the methods, equipment, and materials in the embodiments of this application may be used to implement this application.

[0038] Preparation Example 1 The preparation method of Gastrodia elata polysaccharide extract is as follows: Take dried Gastrodia elata tubers, pulverize to 60-80 mesh, add 60% (v / mL) ethanol aqueous solution at a material-to-liquid ratio of 1:20 (g / mL), and perform ultrasonic-assisted extraction at 60°C with a power of 300W, a frequency of 40kHz, and a time of 45min. Filter and collect the filtrate. Concentrate the filtrate under reduced pressure at 45°C and a vacuum of -0.09MPa to 1 / 5 of its original volume to obtain a concentrated Gastrodia elata polysaccharide solution. Further purification is performed using AB-8 macroporous adsorption resin column chromatography, eluting with 30% (v / mL) ethanol aqueous solution. Collect the eluent and concentrate under reduced pressure to dryness to obtain Gastrodia elata polysaccharide extract powder with a total phenol content (calculated as gallic acid) of not less than 40%.

[0039] Preparation Example 2 The preparation method of the amphiphilic sodium alginate derivative is as follows: Sodium alginate is dissolved in deionized water to prepare a 1.0% sodium alginate aqueous solution. Octylamine and cyclohexylisocyanate are added, with a molar ratio of sodium alginate structural unit: octylamine: cyclohexylisocyanate = 1:0.3:0.3. The pH of the reaction system was adjusted to 3.5 with 1 mol / L HCl aqueous solution, and the reaction was magnetically stirred at room temperature for 24 h. After the reaction was completed, the reaction solution was placed in a dialysis bag (molecular weight cutoff MWCO = 3500 Da) and dialyzed with deionized water for 72 h (changing the dialysate every 8 h) to remove unreacted octylamine, cyclohexylisocyanate, and their byproducts. The dialyzed solution was then freeze-dried to obtain the final product.

[0040] Preparation Example 3 Modified zein was prepared using the following steps: Dissolve 5g sodium caseinate and 10g β-glucan in 100mL deionized water, stir at 300rpm for 12h, then freeze dry. Spread the resulting freeze-dried powder into a glass dish, place it in a reaction chamber, maintain the humidity at 80% with saturated potassium bromide solution, control the temperature at 60℃, and react for 24h to obtain the precursor. Dissolve zein in an 80% ethanol solution, add sodium thiocate and stir until homogeneous to obtain a base solution. Control the mass concentration of zein in the base solution to 3% and the mass concentration of thiocate in the base solution to 0.3%. Dissolve 10g of precursor in 200mL of deionized water and adjust the pH to 6 to obtain a pretreatment solution. Slowly add 50mL of the pretreatment solution to 100mL of the pretreatment solution and stir thoroughly at 800r / min for 1h. Remove the ethanol by rotary evaporation at 40℃, centrifuge, and freeze-dry the supernatant to obtain the final product.

[0041] Example 1 like Figure 1As shown, the Gastrodia elata polysaccharide-peptide complex in this embodiment is a W1 / O / W2 type multiple emulsion, which includes an inner aqueous phase (101), an oil phase (102), and an outer aqueous phase (103). The inner aqueous phase (101) is dispersed in the oil phase (102) in the form of W1 / O primary emulsion droplets (110), and the W1 / O primary emulsion droplets (110) are further dispersed in the outer aqueous phase (103). In the inner aqueous phase (101), the Gastrodia elata polysaccharide extract (105) is distributed in a dissolved state, and the modified zein nanoparticles (106) and the amphiphilic sodium alginate derivative (107) are synergistically assembled around the Gastrodia elata polysaccharide extract (105) to form a nanoscale coating structure; the hydrophobic segments of the amphiphilic sodium alginate derivative (107) are simultaneously embedded in the W1 / O interface, and together with polyglycerol ricinoleate and glyceryl monostearate, they constitute the W1 / O interface composite film (109). The polypeptide composition (108) is distributed in the external aqueous phase (103); at the O / W2 interface, carboxymethyl chitosan and chitosan quaternary ammonium salt are alternately deposited to form a multilayer polyelectrolyte interface film (104).

[0042] The gastrodia polysaccharide-peptide complex in this embodiment was prepared using the following steps: Preparation of the internal aqueous phase: At room temperature, add 10.0 g of glycerol, 1.0 g of sodium chloride, 0.2 g of citric acid, 0.5 g of sodium citrate, and 0.25 g of sodium hyaluronate sequentially to deionized water, stirring at 300 rpm until completely dissolved to obtain the basic internal aqueous phase solution. Add 1.5 g of Gastrodia elata polysaccharide extract to the basic internal aqueous phase solution, stirring at 500 rpm for 30 min under light-protected conditions until completely dissolved. Then add 0.5 g of ascorbic acid and stir for 10 min until dissolved. Finally, add 0.25 g of amphiphilic sodium alginate derivative and 0.5 g of modified zein, stirring at 800 rpm for 20 min at 40℃ until completely dissolved to obtain the internal aqueous phase, with a total mass of 100 g. Adjust the pH of the internal aqueous phase to 5.0 ± 0.1 with 1 mol / L HCl or 1 mol / L NaOH aqueous solution. The internal aqueous phase is filtered through a 0.22 μm microporous membrane for sterilization before use. Preparation of the oil phase: Under a 50°C water bath, mix 72.0g of GTCC, 14.0g of PGPR, 5.0g of GMS, and 0.3g of Vitamin E, and stir at 200rpm for 30 minutes until completely homogeneous to obtain the oil phase. Cool the oil phase to room temperature before use. Preparation of primary emulsion: The inner aqueous phase and the intermediate oil phase were mixed at a mass ratio of 3:7. A two-step emulsification method was used to prepare the primary emulsion: First, at room temperature, the emulsion was pre-emulsified using a high-speed disperser at 8000 rpm for 3 minutes to obtain a crude emulsion; second, the crude emulsion was homogenized twice under 40 MPa pressure using a high-pressure homogenizer to obtain the primary emulsion. The droplet size (D[4,3]) of the primary emulsion was controlled within the range of 0.5-2.0 μm, and the particle size was confirmed by a nanoparticle size analyzer. Before use, the primary emulsion was filtered through a 0.45 μm microporous membrane to remove large particles. Preparation of the external aqueous phase: At room temperature, add 10.0 g of glycerol, 2.5 g of trehalose, 0.1 g of citric acid, 0.4 g of sodium citrate, and 0.05 g of disodium EDTA sequentially to deionized water, stirring at 300 rpm until completely dissolved. Then add 0.4 g of carboxymethyl chitosan and 0.4 g of chitosan quaternary ammonium salt, stirring at 500 rpm for 30 min until completely dissolved. Add 0.25 g of xanthan gum, stirring at 800 rpm for 1 h until completely swollen. Finally, add the peptide composition stock solution, totaling 0.04 g of peptides, stirring at 300 rpm for 15 min until uniformly dispersed. Add 0.5 g of phenoxyethanol and 0.15 g of ethylhexylglycerin, stirring for 5 min to obtain the external aqueous phase, totaling 100 g. Adjust the pH of the external aqueous phase to 5.5 ± 0.1 with 1 mol / L HCl or 1 mol / L NaOH aqueous solution. The external aqueous phase is filtered and sterilized by a 0.22μm microporous membrane before use; the preparation method of the polypeptide composition is as follows: palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, acetyl hexapeptide-8 and copper tripeptide-1 are dissolved in deionized water at a mass ratio of 1:1:0.5:0.3 to prepare a polypeptide stock solution with a mass fraction of 5%, which is stored at 4°C for later use; The primary emulsion and the external aqueous phase were mixed at a mass ratio of 4:6. A W1 / O / W2 multiple emulsion was prepared using a two-step emulsification method. Step 1: At room temperature, emulsify the primary emulsion droplets at 5000 rpm for 2 minutes using a high-speed disperser to uniformly disperse the primary emulsion droplets in the external aqueous phase, forming the basic structure of the multiple emulsion and obtaining the primary W1 / O / W2 emulsion. Step 2: The obtained primary W1 / O / W2 emulsion was allowed to stand at room temperature for 30 min to allow the polyelectrolyte molecules to fully adsorb and rearrange at the O / W2 interface. Then, under low-speed stirring at 100 rpm, a polyelectrolyte replenishment solution (a mixed aqueous solution containing 0.2% carboxymethyl chitosan and 0.2% chitosan quaternary ammonium salt, pH 5.5) was slowly added dropwise to the emulsion at a flow rate of 0.5 mL / min using a syringe pump, with the added amount being 5% of the total emulsion mass. After the addition was complete, low-speed stirring was continued for 30 min to allow the replenished polyelectrolyte to further assemble at the interface, forming a multilayer polyelectrolyte interfacial film. Step 3: Homogenize the emulsion obtained in step 2 once under a pressure of 10 MPa to obtain a multiple emulsion, which is the complex containing Gastrodia elata polysaccharide-peptide.

[0043] Example 2 The difference between this embodiment and Example 1 is that the amount of Gastrodia elata polysaccharide extract used in the aqueous phase is 1.8g, the amount of amphiphilic sodium alginate derivative is 0.3g, and the amount of modified zein is 0.6g. The remaining components and preparation steps are the same as in Example 1.

[0044] Example 3 The difference between this embodiment and Example 1 is that: the amount of Gastrodia elata polysaccharide extract used in the inner aqueous phase is 1.2g, the amount of amphiphilic sodium alginate derivative used is 0.2g, and the amount of modified zein used is 0.4g; the total mass of the polypeptide composition in the outer aqueous phase is 0.05g, and the remaining components and preparation steps are the same as in Example 1.

[0045] Comparative Example 1 1.5g of Gastrodia elata polysaccharide extract and a polypeptide composition (a polypeptide stock solution prepared by mixing palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, acetyl hexapeptide-8, and copper tripeptide-1 in a mass ratio of 1:1:0.5:0.3, with a total polypeptide mass of 0.04g) were directly added to 100g of deionized water. The mixture was stirred until dissolved, and the pH was adjusted to 5.2 to obtain a direct mixed aqueous solution. This comparative example does not contain an emulsion structure, and the Gastrodia elata polysaccharide extract and the polypeptide composition are in the same continuous aqueous phase.

[0046] Comparative Example 2 The difference between this comparative example and Example 1 is that no modified zein was added to the aqueous phase; its amount was made up with deionized water. All other components and preparation steps were the same as in Example 1. This comparative example was used to investigate the contribution of modified zein to the polysaccharide coating and isolation in the aqueous phase.

[0047] Comparative Example 3 The difference between this comparative example and Example 1 is that no amphiphilic sodium alginate derivative was added to the inner aqueous phase; its amount was made up with deionized water. All other components and preparation steps were the same as in Example 1. This comparative example was used to investigate the contribution of the amphiphilic sodium alginate derivative to the enhancement of the W1 / O interface film and the inner phase coating.

[0048] Comparative Example 4 The difference between this comparative example and Example 1 is that the steps of adding the polyelectrolyte replenishment solution and continuing stirring in step 5 are omitted. That is, the layer-by-layer assembly of the polyelectrolyte is not performed; instead, the initial polyelectrolyte in the aqueous phase is naturally adsorbed at the O / W2 interface. All other components and preparation steps are the same as in Example 1. This comparative example is used to examine the contribution of the multilayer polyelectrolyte interfacial film.

[0049] Comparative Example 5 1.5 g of Gastrodia elata polysaccharide extract and the polypeptide composition (total polypeptide mass 0.04 g) were added together to a continuous aqueous phase (composition same as the aqueous phase in Example 1), and mixed with the oil phase at a mass ratio of 6:4. The mixture was dispersed at 8000 rpm for 3 min and homogenized twice under high pressure at 40 MPa to prepare a single O / W type emulsion. In this comparative example, the Gastrodia elata polysaccharide extract and the polypeptide composition were both in a continuous aqueous phase, with only one oil-water interface.

[0050] Performance testing I. Determination of Polysaccharide Isolation Rate Detection methods: Total sugar content was determined using the phenol-sulfuric acid method, and total phenol content was determined using the Folin-phenol method. Total phenol content was used as a tracer index for Gastrodia elata polysaccharide extract. Each sample was centrifuged in an ultrafiltration centrifuge tube (molecular weight cutoff 100 kDa) at 4℃ and 8000 rpm for 30 min to separate the external aqueous phase filtrate. The free phenol content in the filtrate was determined. The polysaccharide isolation rate was calculated using the following formula: Polysaccharide isolation rate = (Total phenol content - External aqueous phase free phenol content) / Total phenol content × 100%.

[0051] Test results: The polysaccharide isolation rate was 96.92% in Example 1, 96.20% in Example 2, and 95.10% in Example 3; 78.40% in Comparative Example 2, 80.60% in Comparative Example 3, and 83.20% in Comparative Example 4. In Comparative Examples 1 and 5, the Gastrodia elata polysaccharide extract and the polypeptide composition were in the same continuous aqueous phase, and there was no isolation structure; the isolation rate was approximately 0%.

[0052] The results showed that the complexes of Examples 1 to 3 could retain a high proportion of Gastrodia elata polysaccharide extract in the inner aqueous phase; after Comparative Examples 2 and 3 were deprived of modified zein and amphiphilic sodium alginate derivative, respectively, the isolation rate decreased by about 16 to 18 percentage points; after Comparative Example 4 was deprived of the multilayer polyelectrolyte interfacial membrane, the isolation rate decreased by about 13 percentage points, indicating that the synergistic coating of the inner aqueous phase and the O / W2 interfacial multilayer membrane both contributed to inhibiting the transinterfacial migration of polysaccharides.

[0053] II. Particle size and storage stability Detection methods: The particle size D[4,3] and polydispersity index of the multiple emulsion were determined by a nanoparticle size analyzer, and the zeta potential was determined by a zeta potential meter. Each sample was stored in the dark at 4℃, 25℃ and 45℃ respectively, and the particle size was measured at 0 days, 30 days, 60 days and 90 days. Another sample was centrifuged at 3000rpm for 30min to observe whether there was stratification or floating oil.

[0054] Test results: In Example 1, after 90 days of storage at 25℃, the particle size D[4,3] increased from 8.6 μm to 9.1 μm, with a particle size change rate of 5.8%; after 30 days of storage at 45℃, the particle size was 9.4 μm; after centrifugation at 3000 rpm for 30 min, there was no stratification, no floating oil, and no demulsification. In Examples 2 and 3, the particle size change rates after 90 days of storage at 25℃ were 6.3% and 6.9%, respectively. In Comparative Examples 2, 3, and 4, the particle size change rates after 90 days of storage at 25℃ were 12.7%, 11.9%, and 10.8%, respectively, with Comparative Example 2 showing slight stratification on day 60. In Comparative Example 5, obvious stratification and floating oil appeared after 30 days of storage at 25℃. In Comparative Example 1, the solution showed obvious browning after 3 days of storage at 45℃ (color difference ΔE 6.8), and the color difference further increased after 7 days of storage (ΔE 11.2), with the peptide content decreasing by 24.6% compared to the initial value.

[0055] The results showed that the complex in the examples had good thermodynamic and storage stability; the synergistic coating of the inner aqueous phase and the interfacial multilayer film could delay Austmann ripening and droplet coalescence, while in the direct mixing system, polysaccharides and phenols interacted with peptides, leading to browning and peptide degradation.

[0056] III. In vitro release test Detection method: The modified Franz diffusion cell method was used, with pH 5.5 phosphate buffer as the receiving solution, and the cumulative release rate of Gastrodia elata polysaccharide extract (calculated as total phenols) was determined within 24 h and 72 h at 32℃ and 300 rpm.

[0057] Test results: The cumulative release rates of Example 1 at 24h and 72h were 4.8% and 6.9%, respectively; those of Comparative Example 2 were 21.3% and 27.5%, respectively; those of Comparative Example 3 were 18.9% and 25.2%, respectively; those of Comparative Example 4 were 12.6% and 16.8%, respectively; and those of Comparative Example 5 reached 92.4% at 24h.

[0058] The results showed that the multiple emulsions in the examples had a strong retention capacity for Gastrodia elata polysaccharides, with a cumulative release rate of less than 7% after 72 hours; the absence of any isolation structure led to a significant increase in the release rate.

[0059] IV. Antioxidant Activity Assay Detection methods: DPPH free radical scavenging method, ABTS cationic free radical scavenging method, and FRAP ferric reduction method. Samples were diluted to a concentration of 0.5 mg / mL for Gastrodia elata polysaccharide extract before determination; storage stability was assessed using samples stored at 45℃ in the dark for 28 days.

[0060] Test results: The DPPH scavenging rate of the Gastrodia elata polysaccharide extract raw material was 71.6%, the ABTS scavenging rate was 78.9%, and the FRAP value was 2.86 mmol TE / g. The freshly prepared Example 1 had a DPPH scavenging rate of 83.4%, an ABTS scavenging rate of 89.2%, and a FRAP value of 3.42 mmol TE / g; after storage at 45℃ for 28 days, the DPPH scavenging rate of Example 1 remained at 79.1%, with a retention rate of 94.8%. The DPPH scavenging rate of Comparative Example 1, when freshly prepared, was 74.2%, but decreased to 52.3% after storage at 45℃ for 28 days, with a retention rate of only 70.5%.

[0061] The results showed that the activity of the gastrodia polysaccharide extract and polypeptide composition remained good in the partitioned isolation system of the examples, and the antioxidant capacity was not inhibited when coexisting with the polypeptide; in Comparative Example 1, the phenolic components were greatly lost due to oxidation and reaction with the polypeptide, and the antioxidant activity decreased significantly.

[0062] V. Cell Experiments Detection methods: First, the cell viability of human immortalized keratinocytes (HaCaT) after 24 hours of sample treatment was determined using the CCK-8 assay, with a sample concentration of 0.5 mg / mL. Second, a HaCaT oxidative damage model induced by 400 μM hydrogen peroxide was established, and the cell survival rate after 24 hours of sample pretreatment was determined. Third, the amount of type I collagen synthesized in human skin fibroblasts (HSF) after 72 hours of treatment with the sample (0.2 mg / mL) was determined using a type I collagen ELISA kit, with a blank control as 100%. Fourth, a 20 mJ / cm² UVB irradiation model of HSF was established, and the inhibition rate of the sample on matrix metalloproteinase-1 (MMP-1) secretion was determined.

[0063] Results: In Example 1, HaCaT cell viability was 98.6% at 0.5 mg / mL, with no cytotoxicity. The cell survival rate in the hydrogen peroxide model group was 52.4%; the survival rate in the Example 1 pretreatment group was 91.3%, and in the Comparative Example 1 pretreatment group it was 68.5%. Regarding HSF-induced collagen synthesis, Example 1 showed 158.4% (i.e., a promotion rate of 58.4%) compared to the blank control, Example 2 showed 152.8%, and Example 3 showed 149.6%; Comparative Example 1 showed 121.5%, Comparative Example 2 showed 134.2%, Comparative Example 3 showed 136.0%, Comparative Example 4 showed 139.1%, and Comparative Example 5 showed 128.7%. Regarding MMP-1 inhibition rate, Example 1 showed 63.2%, and Comparative Example 1 showed 31.5%.

[0064] The results showed that the complex in the examples was non-cytotoxic, effectively protected cells from oxidative damage, promoted type I collagen synthesis, and inhibited UVB-induced MMP-1 expression; the efficacy of each comparative example was significantly reduced due to the lack of the isolation structure.

[0065] VI. Evaluation of Human Efficacy Methods: Thirty healthy female subjects aged 25 to 55 years with dry to combination skin types were randomly assigned to groups. Samples were applied twice daily, morning and evening, for 28 consecutive days. Skin elasticity (R2) was measured before application and on days 14 and 28 after application. Transepidermal water loss (TEWL) was measured using a skin elasticity meter, stratum corneum moisture content was measured using a skin moisture meter, crow's feet depth (Ra) and skin roughness (Rz) were measured using a rapid 3D skin imaging system, and melanin index was measured using a skin melanin meter. A blank matrix without the complex was used as a matrix control.

[0066] Test results: After 28 days of use, in Example 1, the subjects showed a 22.6% increase in skin elasticity (R2), a 19.8% decrease in TEWL, an 18.5% increase in stratum corneum moisture content, a 16.3% decrease in wrinkle depth (Ra), a 14.7% decrease in skin roughness (Rz), and an 8.2% decrease in melanin index; the corresponding data for Example 2 were a 20.4% increase in elasticity, a 17.6% decrease in TEWL, and a 14.5% decrease in wrinkle depth; and for Example 3, a 19.1% increase in elasticity, a 16.5% decrease in TEWL, and a 13.2% decrease in wrinkle depth. Comparative Example 1 showed a 9.8% increase in elasticity, an 8.9% decrease in TEWL, and a 6.4% reduction in wrinkle depth; Comparative Example 2 showed a 14.6% increase in elasticity, a 12.1% decrease in TEWL, and a 9.8% reduction in wrinkle depth; Comparative Example 3 showed a 15.2% increase in elasticity, a 12.8% decrease in TEWL, and a 10.3% reduction in wrinkle depth; Comparative Example 4 showed a 16.4% increase in elasticity, a 13.5% decrease in TEWL, and a 10.9% reduction in wrinkle depth; and Comparative Example 5 showed a 12.3% increase in elasticity, a 10.2% decrease in TEWL, and an 8.1% reduction in wrinkle depth. The matrix control showed a 4.1% increase in elasticity, a 3.6% decrease in TEWL, and a 2.2% reduction in wrinkle depth.

[0067] like Figure 5 As shown, the distribution of the embodiment and the comparative examples in the three dimensions of skin elasticity improvement rate, TEWL reduction rate, and wrinkle depth reduction rate is clearly distinguishable: the bubble size of the embodiment is significantly higher than that of the comparative examples in all three dimensions, and the bubble size (representing the collagen synthesis rate) is larger; the efficacy of comparative examples 2 to 4 decreases in that they are respectively lacking modified zein, amphiphilic sodium alginate derivative or multilayer polyelectrolyte interface membrane, indicating that each isolation structure makes an independent contribution to the efficacy.

[0068] VII. Safety Evaluation Testing method: Thirty subjects were selected for a 48-hour closed human skin patch test, and the adverse skin reaction was judged according to the "Cosmetic Safety Technical Specifications" skin adverse reaction grading standard.

[0069] Test results: Patch tests for Examples 1 to 3 were all negative. No subjects experienced adverse reactions such as erythema, edema, or papules. The skin irritation index was 0, indicating that the complex has good safety.

[0070] VIII. Response Surface Optimization Experiment To investigate the interactive effects of the dosage of key components in the internal aqueous phase on the polysaccharide isolation rate, a three-factor, three-level Box-Behnken design was used to investigate the dosage of Gastrodia elata polysaccharide extract (m1), modified zein (m2), and amphiphilic sodium alginate derivative (m3) as the factors, with the polysaccharide isolation rate (Y, %) as the response value. The codes and levels for each factor were as follows: m1 was 0.5, 1.5, and 2.5 g / 100 g (internal aqueous phase), with code values ​​X1 of -1, 0, and 1, respectively; m2 was 0.2, 0.5, and 0.8 g / 100 g, with code values ​​X2 of -1, 0, and 1, respectively; m3 was 0.10, 0.25, and 0.40 g / 100 g, with code values ​​X3 of -1, 0, and 1, respectively.

[0071] The symbols in the formula are defined as follows: Y is the polysaccharide isolation rate (%); X1 is the coded value of the amount of Gastrodia elata polysaccharide extract added; X2 is the coded value of the amount of modified zein added; X3 is the coded value of the amount of amphiphilic sodium alginate derivative added; m1 is the amount of Gastrodia elata polysaccharide extract added (g / 100g aqueous phase); m2 is the amount of modified zein added (g / 100g aqueous phase); m3 is the amount of amphiphilic sodium alginate derivative added (g / 100g aqueous phase); F is the F-statistic of the analysis of variance; p is the significance probability; R is the coefficient of determination.

[0072] The encoding relationship is: X1=(m1-1.5) / 1.0, X2=(m2-0.5) / 0.3, X3=(m3-0.25) / 0.15.

[0073] A total of seventeen experiments were conducted, with groups 13 to 17 being center-point replicate experiments. The polysaccharide isolation rate results for each experiment are as follows: Group 1, coded as (-1, -1, 0), i.e., m1=0.5g / 100g, m2=0.2g / 100g, m3=0.25g / 100g, Y=87.01%; Group 2, coded as (1, -1, 0), i.e., m1=2.5g / 100g, m2=0.2g / 100g, m3=0.25g / 100g, Y=85.47%; Group 3, coded (-1, 1, 0), i.e., m1=0.5g / 100g, m2=0.8g / 100g, m3=0.25g / 100g, Y=86.73%; Group 4, coded (1, 1, 0), i.e., m1=2.5g / 100g, m2=0.8g / 100g, m3=0.25g / 100g, Y=88.69%; Group 5, coded (-1, 0, -1), i.e., m1=0.5g / 100g, m2=0.5g / 100g, m3=0.10g / 100g, Y=88.19%; Group 6, coded (1, 0, -1), i.e., m1=2.5g / 100g, m2=0.5g / 100g, m3=0.10g / 100g, Y=87.32%; Group 7, coded (-1, 0, 1), i.e., m1=0.5g / 100g, m2=0.5g / 100g, m3=0.40g / 100g, Y=87.26%; Group 8, coded (1, 0, 1), i.e., m1=2.5g / 100g, m2=0.5g / 100g, m3=0.40g / 100g, Y=89.61%; Group 9, coded (0, -1, -1), i.e., m1=1.5g / 100g, m2=0.2g / 100g, m3=0.10g / 100g, Y=87.83%; Group 10, coded (0, 1, -1), i.e., m1=1.5g / 100g, m2=0.8g / 100g, m3=0.10g / 100g, Y=86.54%; Group 11, coded (0, -1, 1), i.e., m1=1.5g / 100g, m2=0.2g / 100g, m3=0.40g / 100g, Y=85.81%; Group 12, coded (0, 1, 1), i.e., m1=1.5g / 100g, m2=0.8g / 100g, m3=0.40g / 100g, Y=89.99%; Groups 13 to 17 are coded as (0, 0, 0), i.e., m1=1.5g / 100g, m2=0.5g / 100g, m3=0.25g / 100g, and Y is 96.88%, 97.12%, 96.66%, 96.97%, and 96.99%, respectively.

[0074] Multiple quadratic regression was performed on the experimental data to obtain the regression equation of polysaccharide isolation rate on the encoded value: Y=96.924+0.238X1+0.729X2+0.349X3-4.698X1²-5.251X2²-4.131X3²+0.875X1X2+0.805X1X3+1.368X2X3 Analysis of variance showed that the regression model was highly significant (F=1002.11, p<0.0001), with no significant lack-of-fit term (F=1.62, p=0.319). The coefficient of determination R² was 0.9992, and the adjusted coefficient of determination was 0.9982, indicating that the model fits well and can be used for response prediction. The regression equation shows that the coefficients of the linear terms for each factor are all positive, while the coefficients of the quadratic terms are all negative, indicating that there is a plateau region of maximum value in the response surface at medium to high levels for the three component dosages.

[0075] like Figure 2 As shown, when m3 is fixed at the central level (X3=0), the polysaccharide isolation rate first increases and then decreases with the increase of m1 and m2, and the response surface exhibits a distinct arch shape. The interaction term coefficient between m1 and m2 is 0.875. Figure 3 As shown, the interaction coefficient between m1 and m3 is 0.805; Figure 4 As shown, the interaction coefficient between m2 and m3 is 1.368, indicating that the amount of modified zein and amphiphilic sodium alginate derivative has the most significant interaction effect on the isolation rate, and the two synergistically enhance the inner aqueous phase coating and the interfacial membrane structure.

[0076] Taking the first partial derivative of the regression equation and setting it to zero yields the optimal conditions: X1=0.038, X2=0.080, X3=0.059, i.e., m1=1.54g / 100g, m2=0.52g / 100g, m3=0.26g / 100g, predicting a polysaccharide isolation rate of 96.97%. Three validation experiments were conducted under these conditions, with measured isolation rates of 96.95%, 97.01%, and 96.94%, respectively, and a mean of 96.97%, consistent with the predicted value. The formulation of Example 1 (m1=1.5g / 100g, m2=0.5g / 100g, m3=0.25g / 100g) is located within the response plateau region, and its predicted isolation rate is 96.92%, which is less than 0.1 percentage points different from the predicted value under the optimal conditions. Considering the raw material cost and process simplicity, the formulation of Example 1 is the preferred formulation of this application. The formulations of Example 2 and Example 3 are also located within the plateau region.

[0077] Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. A complex containing Gastrodia elata polysaccharide-peptide, characterized in that: The complex has a W1 / O / W2 type multiple emulsion structure, including an inner aqueous phase, an oil phase, and an outer aqueous phase; the inner aqueous phase contains Gastrodia elata polysaccharide extract, an amphiphilic sodium alginate derivative, and modified zein; the oil phase contains caprylic / capric triglyceride, polyglycerol ricinoleate, and glyceryl monostearate; the outer aqueous phase contains a polypeptide composition and a polyelectrolyte complex, the polyelectrolyte complex comprising carboxymethyl chitosan and chitosan quaternary ammonium salt.

2. The gastrodia polysaccharide-peptide complex according to claim 1, characterized in that: Based on a total mass of 100 parts, the internal aqueous phase contains 8 to 12 parts glycerol, 0.8 to 1.2 parts sodium chloride, 0.15 to 0.25 parts citric acid, 0.4 to 0.6 parts sodium citrate, 0.2 to 0.3 parts sodium hyaluronate, 0.4 to 0.6 parts ascorbic acid, 1.0 to 2.0 parts gastrodia elata polysaccharide extract, 0.2 to 0.3 parts amphiphilic sodium alginate derivative, 0.4 to 0.6 parts modified zein, and the remainder is water. The pH value of the internal aqueous phase is 5.0 ± 0.

1.

3. The gastrodia polysaccharide-peptide complex according to claim 1, characterized in that: Based on a total mass of 100 parts, the oil phase contains 65 to 85 parts of caprylic / capric triglyceride, 8 to 20 parts of polyglycerol ricinoleate, 2 to 8 parts of glyceryl monostearate, and 0.1 to 1 part of vitamin E.

4. The gastrodia polysaccharide-peptide complex according to claim 1, characterized in that: Based on a total mass of 100 parts, the external aqueous phase contains 8 to 12 parts glycerol, 2 to 3 parts trehalose, 0.08 to 0.12 parts citric acid, 0.3 to 0.5 parts sodium citrate, 0.03 to 0.08 parts disodium EDTA, 0.3 to 0.5 parts carboxymethyl chitosan, 0.3 to 0.5 parts chitosan quaternary ammonium salt, 0.2 to 0.3 parts xanthan gum, 0.03 to 0.05 parts polypeptide composition, 0.4 to 0.6 parts phenoxyethanol, 0.1 to 0.2 parts ethylhexylglycerol, and the balance being water. The pH value of the external aqueous phase is 5.5 ± 0.

1.

5. The gastrodia polysaccharide-peptide complex according to claim 1, characterized in that: The polypeptide composition consists of palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, acetyl hexapeptide-8, and copper tripeptide-1 in a mass ratio of 1:1:0.5:0.

3.

6. The gastrodia polysaccharide-peptide complex according to claim 1, characterized in that: The gastrodia polysaccharide extract was obtained by ultrasonic-assisted ethanol extraction and macroporous adsorption resin column chromatography purification from dried gastrodia tubers. The total phenol content of the gastrodia polysaccharide extract, calculated as gallic acid, is not less than 40%.

7. The gastrodia polysaccharide-peptide complex according to claim 1, characterized in that: The amphiphilic sodium alginate derivative is an amphiphilic sodium alginate derivative obtained by grafting sodium alginate with octylamine and cyclohexylisocyanate via the Ugi reaction.

8. The gastrodia polysaccharide-peptide complex according to claim 1, characterized in that: The modified zein is a modified zein nanoparticle, which is formed by the complexation of lipoic acid-modified zein and the Maillard reaction product of sodium caseinate-β-glucan.

9. A method for preparing a gastrodia polysaccharide-peptide complex, characterized in that: Includes the following steps: An internal aqueous phase was prepared, wherein the internal aqueous phase contained Gastrodia elata polysaccharide extract, amphiphilic sodium alginate derivative, and modified zein; An oil phase is prepared, the oil phase containing oils and lipophilic emulsifiers; the inner aqueous phase is mixed with the oil phase and subjected to high-speed dispersion and high-pressure homogenization in sequence to prepare a W1 / O primary emulsion; an outer aqueous phase is prepared, the outer aqueous phase containing a polypeptide composition and a polyelectrolyte; the primary emulsion is mixed with the outer aqueous phase and subjected to high-speed dispersion and polyelectrolyte layer-by-layer assembly in sequence to prepare a W1 / O / W2 multiple emulsion.

10. The use of a gastrodia polysaccharide-peptide complex as described in any one of claims 1 to 8 in the preparation of repair and / or anti-aging cosmetics, characterized in that: The repair and / or anti-aging cosmetics contain a gastrodia polysaccharide-peptide complex and cosmetically acceptable excipients.

Images